Application 091144
- Type
- ANDA
- Sponsor
- CIPLA
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | ABACAVIR SULFATE AND LAMIVUDINE | ABACAVIR SULFATE; LAMIVUDINE | TABLET;ORAL | EQ 600MG BASE;300MG | No | No |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 69097-362 | Abacavir and Lamivudine | Abacavir and lamivudine | Cipla USA Inc. | ANDA | Current |
| 69097-362 | Abacavir and Lamivudine | Abacavir and lamivudine | Cipla USA Inc. | ANDA | Current |
| 69097-362 | Abacavir and Lamivudine | Abacavir and lamivudine | Cipla USA Inc. | ANDA | Current |
| 69097-362 | Abacavir and Lamivudine | Abacavir and lamivudine | Cipla USA Inc. | ANDA | Current |
| 69097-362 | Abacavir and Lamivudine | Abacavir and lamivudine | Cipla USA Inc. | ANDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 9321 | ORIG | 2012-02-02 |